EyePoint to Present at 2025 RBC Capital Markets Ophthalmology Virtual Conference
EyePoint Pharmaceuticals (NASDAQ: EYPT), a leading developer of therapeutics for serious retinal diseases, has announced its upcoming participation in the 2025 RBC Capital Markets Ophthalmology Virtual Conference.
The company's President and CEO, Jay S. Duker, M.D., will engage in a fireside chat scheduled for April 4, 2025, at 10:00 a.m. ET. Investors and interested parties can access the live webcast and subsequent replay through the Investors section on EyePoint's website at www.eyepointpharma.com.
EyePoint Pharmaceuticals (NASDAQ: EYPT), un importante sviluppatore di terapie per gravi malattie retiniche, ha annunciato la sua prossima partecipazione alla Conferenza Virtuale di Oftalmologia RBC Capital Markets 2025.
Il Presidente e CEO dell'azienda, Jay S. Duker, M.D., parteciperà a una conversazione informale programmata per il 4 aprile 2025, alle 10:00 ET. Gli investitori e le parti interessate possono accedere alla diretta e alla successiva registrazione attraverso la sezione Investitori del sito web di EyePoint all'indirizzo www.eyepointpharma.com.
EyePoint Pharmaceuticals (NASDAQ: EYPT), un importante desarrollador de terapias para enfermedades retinianas graves, ha anunciado su próxima participación en la Conferencia Virtual de Oftalmología de RBC Capital Markets 2025.
El Presidente y CEO de la compañía, Jay S. Duker, M.D., participará en una charla informal programada para el 4 de abril de 2025, a las 10:00 a.m. ET. Los inversores y partes interesadas pueden acceder a la transmisión en vivo y a la repetición posterior a través de la sección de Inversores en el sitio web de EyePoint en www.eyepointpharma.com.
EyePoint Pharmaceuticals (NASDAQ: EYPT), 심각한 망막 질환을 위한 치료제를 개발하는 선도 기업, 2025 RBC 캐피탈 마켓 안과 가상 컨퍼런스에 참여할 것이라고 발표했습니다.
회사의 회장 겸 CEO인 Jay S. Duker, M.D.는 2025년 4월 4일 오전 10시 ET에 예정된 대담에 참여할 예정입니다. 투자자 및 관심 있는 분들은 EyePoint 웹사이트의 투자자 섹션을 통해 라이브 웹캐스트와 이후 재생을 이용할 수 있습니다. www.eyepointpharma.com.
EyePoint Pharmaceuticals (NASDAQ: EYPT), un développeur de premier plan de thérapies pour les maladies rétiniennes graves, a annoncé sa prochaine participation à la Conférence Virtuelle d'Ophtalmologie RBC Capital Markets 2025.
Le Président et CEO de l'entreprise, Jay S. Duker, M.D., participera à une discussion informelle prévue pour le 4 avril 2025 à 10h00 ET. Les investisseurs et les parties intéressées peuvent accéder à la diffusion en direct et à la rediffusion ultérieure via la section Investisseurs du site web d'EyePoint à l'adresse www.eyepointpharma.com.
EyePoint Pharmaceuticals (NASDAQ: EYPT), ein führender Entwickler von Therapeutika für schwere Netzhauterkrankungen, hat seine bevorstehende Teilnahme an der 2025 RBC Capital Markets Augenheilkunde Virtuelle Konferenz angekündigt.
Der Präsident und CEO des Unternehmens, Jay S. Duker, M.D., wird an einem geplanten Gespräch teilnehmen, das für den 4. April 2025 um 10:00 Uhr ET angesetzt ist. Investoren und Interessierte können über den Investorenbereich auf der Website von EyePoint unter www.eyepointpharma.com auf das Live-Webcast und die anschließende Wiederholung zugreifen.
- None.
- None.
WATERTOWN, Mass., March 27, 2025 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious retinal diseases, today announced that Jay S. Duker, M.D., President and Chief Executive Officer of EyePoint, will participate in a fireside chat at the 2025 RBC Capital Markets Ophthalmology Conference on Friday, April 4, 2025 at 10:00 a.m. ET.
A live webcast and subsequent archived replay of the fireside chat may be accessed via the Investors section of the Company website at www.eyepointpharma.com.
About EyePoint
EyePoint (Nasdaq: EYPT) is a clinical-stage biopharmaceutical company committed to developing and commercializing innovative therapeutics to help improve the lives of patients with serious retinal diseases. The Company's pipeline leverages its proprietary bioerodible Durasert E™ technology for sustained intraocular drug delivery. The Company’s lead product candidate, DURAVYU™ is an investigational sustained delivery treatment for VEGF-mediated retinal diseases combining vorolanib, a selective and patent-protected tyrosine kinase inhibitor with bioerodible Durasert E™. Supported by robust safety and efficacy data to date, DURAVYU is presently in Phase 3 global, pivotal clinical trials for wet age-related macular degeneration (wet AMD), the leading cause of vision loss among people 50 years of age and older in the United States and recently completed a Phase 2 clinical trial in diabetic macular edema (DME). Based on positive Phase 2 results from the VERONA clinical trial in DME, EyePoint anticipates meeting with U.S. and ex-U.S. regulatory agencies in the second quarter of 2025 to confirm plans for a pivotal program.
Pipeline programs include EYP-2301, a TIE-2 agonist, razuprotafib, formulated in Durasert E™ to potentially improve outcomes in serious retinal diseases. The proven Durasert® drug delivery technology has been safely administered to thousands of patient eyes across four U.S. FDA approved products in multiple disease indications. EyePoint Pharmaceuticals is headquartered in Watertown, Massachusetts.
Vorolanib is licensed to EyePoint exclusively by Equinox Sciences, a Betta Pharmaceuticals affiliate, for the localized treatment of all ophthalmic diseases outside of China, Macao, Hong Kong and Taiwan.
DURAVYU™ has been conditionally accepted by the FDA as the proprietary name for EYP-1901. DURAVYU is an investigational product; it has not been approved by the FDA. FDA approval and the timeline for potential approval is uncertain.
Investors:
Christina Tartaglia
Precision AQ
Direct: 212-698-8700
christina.tartaglia@precisionaq.com
Media Contact:
Amy Phillips
Green Room Communications
Direct: 412-327-9499
aphillips@greenroompr.com
